NCT04227509View on ClinicalTrials.gov

Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.

DRUG

Placebo

normal saline will be administered as a 30 minute IV infusion every 3 weeks.

Trial Locations (1)

110-744

RECRUITING

Department of Internal Medicine, Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER